| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2796844 | Diabetes Research and Clinical Practice | 2013 | 4 Pages |
Abstract
Incretin based therapies are known to have pleotropic benefits in type 2 diabetes but have not been studied in new onset type 1 diabetes. In this randomized, open label study, we investigated the effect of the addition of exenatide or sitagliptin to insulin in patients with new onset type 1 diabetes. Our data suggest that the addition of exenatide and sitagliptin decreases insulin requirements without increasing endogenous insulin production and hypoglycemic events.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Endocrinology
Authors
K.V.S. Hari Kumar, Altamash Shaikh, Pitambar Prusty,